Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial

JACC: Heart Failure

Volumn 4, Issue 2, 2016, Pages 109-115

  Fiuzat, Mona ^a   Wojdyla, Daniel ^a   Pina, Ileana ^b   Adams, Kirkwood ^c   Whellan, David ^d   O'Connor, Christopher M ^a,e  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e INOVA HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

Beta blockers; Dose; Exercise; Heart failure; Heart rate; Mortality

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DOSE TITRATION; EXERCISE; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC DYSFUNCTION; CAUSE OF DEATH; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; EPIDEMIOLOGY; HEART LEFT VENTRICLE FUNCTION; OUTPATIENT; PATHOPHYSIOLOGY; PHYSIOLOGY; SURVIVAL RATE; SYSTOLE; TIME FACTOR; TREATMENT OUTCOME; TRENDS; UNITED STATES;

ADRENERGIC BETA-ANTAGONISTS; CAUSE OF DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEART RATE; HUMANS; MALE; OUTPATIENTS; SURVIVAL RATE; SYSTOLE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VENTRICULAR FUNCTION, LEFT;

EID: 84959099950     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2015.09.002     Document Type: Article

References (17)

1. Bristow M.R. Treatment of chronic heart failure with beta-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res 2011, 109:1176-1194.
2. Bristow M.R., Gilbert E.M., Abraham W.T., et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996, 94:2807-2816. for the MOCHA Investigators.
3. Fiuzat M., Wojdyla D., Kitzman D., et al. Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. J Am Coll Cardiol 2012, 60:208-215.
4. Pocock S.J., Wang D., Pfeffer M.A., et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006, 27:65-75.
5. Böhm M., Swedberg K., Komajda M., et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010, 376:886-894.
6. Metra M., Torp-Pedersen C., Swedberg K., et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J 2005, 26:2259-2268.
7. McAlister F.A., Wiebe N., Ezekowitz J.A., Leung A.A., Armstrong P.W. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009, 150:784-794.
8. Flannery G., Gehrig-Mills R., Billah B., Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 2008, 101:865-869.
9. Swedberg K., Komajda M., Böhm M., et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010, 376:875-885. [published correction appears in Lancet 2010;376:1988].
10. O'Connor C.M., Whellan D.J., Lee K.L., et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009, 301:1439-1450. for the HF-ACTION Investigators.
11. Whellan D.J., O'Connor C.M., Lee K.L., et al. Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale. Am Heart J 2007, 153:201-211. on behalf of the HF-ACTION Trial Investigators.
12. O'Connor C.M., Whellan D.J., Wojdyla D., et al. Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction: the HF-ACTION predictive risk score model. Circ Heart Fail 2012, 5:63-71.
13. Wikstrand J., Hjalmarson A., Waagstein F., et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol 2002, 40:491-498. MERIT-HF Study Group.
14. Gullestad L., Wikstrand J., Deedwania P., et al. What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol 2005, 45:252-259. MERIT-HF Study Group.
15. Fonarow G.C., Abraham W.T., Albert N.M., et al. Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure). Am J Cardiol 2008, 102:1524-1529.
16. Yancy C.W., Fonarow G.C., Albert N.M., et al. Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. Am Heart J 2009, 157:754-762.e752.
17. Dierckx R., Cleland J.G., Parsons S., et al. Prescribing patterns to optimize heart rate: analysis of 1,000 consecutive outpatient appointments to a single heart failure clinic over a 6-month period. J Am Coll Cardiol HF 2015, 3:224-230.